Akademik Veri Yönetim Sistemi
ERS International Congress, Milan, İtalya, 9 - 13 Eylül 2023, ss.1
Introduction:The advent of
omalizumab(OML) had a major impact on the management of severe allergic asthma,
however it has a very high cost.
Aims:To evaluate the cost-effectiveness of
standard-of-care treatment(SoC) to SoC+omalizumab (OML+Soc) in patients with
severe asthma using real-world prospective clinical data.
Methods:A total of 206 patients with severe astma,
including 126 of whom were in the OML+SoC group and 80 in the SoC group, were
followed for 12 months to evaluate their asthma status and quality of life.
Cost data for this patient-level economic evaluations were sourced from the
database of the hospitals and expressed in Turkish Lira(₺). Efficacy data were
obtained by Asthma Control Test for asthma status, and the 5-level
EQ-5D-5L version and the Asthma Quality of Life Scale for quality of life. A
Markov model with 2-week cycles was specified, comparing costs and treatment
effects of SoC vs OML+SoC over a lifetime from the Turkish payer perspective.
Results:Per-patient costs were ₺23,607.08 in the SoC
arm and ₺425,329.81 in the OML+Soc arm, for a difference of ₺401,722.74. Life
years(LY) and quality-adjusted life years(QALY) were 13.60 and 10.08,
respectively, in the SoC group; and 21.26 and 13.35, respectively, in the
OML+SoC group, for differences of 7.66 LYs and 3.27 QALYs. This yielded an
incremental cost-effectiveness ratio of an additional ₺52,427.04 to gain 1 LY
and an incremental cost-utility ratio of an incremental ₺122,675.57 to gain 1
QALY; the latter being below the ₺156,948 willingness-to-pay threshold for
Turkey referenced by WHO.
Conclusion:This data suggests thatOML+Soc is
cost-effective for severe asthma from the public payer perspective